305 related articles for article (PubMed ID: 26239651)
1. PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development.
Ivens IA; Achanzar W; Baumann A; Brändli-Baiocco A; Cavagnaro J; Dempster M; Depelchin BO; Rovira AR; Dill-Morton L; Lane JH; Reipert BM; Salcedo T; Schweighardt B; Tsuruda LS; Turecek PL; Sims J
Toxicol Pathol; 2015 Oct; 43(7):959-83. PubMed ID: 26239651
[TBL] [Abstract][Full Text] [Related]
2. PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs.
Turecek PL; Bossard MJ; Schoetens F; Ivens IA
J Pharm Sci; 2016 Feb; 105(2):460-475. PubMed ID: 26869412
[TBL] [Abstract][Full Text] [Related]
3. Scientific and Regulatory Policy Committee Points to Consider: Histopathologic Evaluation in Safety Assessment Studies for PEGylated Pharmaceutical Products.
Irizarry Rovira AR; Bennet BM; Bolon B; Braendli-Baiocco A; Chandra S; Fleurance R; Garman R; Hutto D; Lane J; Romeike A; Sargeant A; Zimmerman B
Toxicol Pathol; 2018 Aug; 46(6):616-635. PubMed ID: 30092727
[TBL] [Abstract][Full Text] [Related]
4. Nonclinical Safety Assessment of a Long-Acting Recombinant PEGylated Factor Eight (BAY 94-9027) With a 60 kDa PEG.
Ivens IA; Banczyk D; Gutberlet K; Jackman S; Vauléon S; Frisk AL
Toxicol Pathol; 2019 Jul; 47(5):585-597. PubMed ID: 31132933
[TBL] [Abstract][Full Text] [Related]
5. Adverse vacuolation in multiple tissues in cynomolgus monkeys following repeat-dose administration of a PEGylated protein.
Fletcher AM; Tellier P; Douville J; Mansell P; Graziano MJ; Mangipudy RS; Brodie TA; Achanzar WE
Toxicol Lett; 2019 Dec; 317():120-129. PubMed ID: 31580884
[TBL] [Abstract][Full Text] [Related]
6. Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates.
Stidl R; Fuchs S; Bossard M; Siekmann J; Turecek PL; Putz M
Haemophilia; 2016 Jan; 22(1):54-64. PubMed ID: 26219204
[TBL] [Abstract][Full Text] [Related]
7. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies.
Webster R; Didier E; Harris P; Siegel N; Stadler J; Tilbury L; Smith D
Drug Metab Dispos; 2007 Jan; 35(1):9-16. PubMed ID: 17020954
[TBL] [Abstract][Full Text] [Related]
8. The impact of PEGylation on biological therapies.
Veronese FM; Mero A
BioDrugs; 2008; 22(5):315-29. PubMed ID: 18778113
[TBL] [Abstract][Full Text] [Related]
9. Drug development and nonclinical to clinical translational databases: past and current efforts.
Monticello TM
Toxicol Pathol; 2015 Jan; 43(1):57-61. PubMed ID: 25389276
[TBL] [Abstract][Full Text] [Related]
10. PEGylation of therapeutic proteins.
Jevsevar S; Kunstelj M; Porekar VG
Biotechnol J; 2010 Jan; 5(1):113-28. PubMed ID: 20069580
[TBL] [Abstract][Full Text] [Related]
11. PEG-modified biopharmaceuticals.
Bailon P; Won CY
Expert Opin Drug Deliv; 2009 Jan; 6(1):1-16. PubMed ID: 19236204
[TBL] [Abstract][Full Text] [Related]
12. Magnetic Resonance and Ultrastructural Characterization of PEGylation-associated Vacuolation in Nonclinical Models.
Forest T; Xu Q; Kuruvilla S; Vu H; Vlasakova K; Glaab WE; Hines C; Xun S
Toxicol Pathol; 2017 Jul; 45(5):604-613. PubMed ID: 28673196
[TBL] [Abstract][Full Text] [Related]
13. Treatment-induced and Pre-existing Anti-peg Antibodies: Prevalence, Clinical Implications, and Future Perspectives.
Gaballa SA; Shimizu T; Ando H; Takata H; Emam SE; Ramadan E; Naguib YW; Mady FM; Khaled KA; Ishida T
J Pharm Sci; 2024 Mar; 113(3):555-578. PubMed ID: 37931786
[TBL] [Abstract][Full Text] [Related]
14. Antibodies against polyethylene glycol in human blood: A literature review.
Hong L; Wang Z; Wei X; Shi J; Li C
J Pharmacol Toxicol Methods; 2020; 102():106678. PubMed ID: 31981619
[TBL] [Abstract][Full Text] [Related]
15. Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells.
Lebrec H; Narayanan P; Nims R
J Appl Toxicol; 2010 Jul; 30(5):387-96. PubMed ID: 20589744
[TBL] [Abstract][Full Text] [Related]
16. Emerging PEGylated non-biologic drugs.
Park EJ; Choi J; Lee KC; Na DH
Expert Opin Emerg Drugs; 2019 Jun; 24(2):107-119. PubMed ID: 30957581
[No Abstract] [Full Text] [Related]
17. Emerging PEGylated drugs.
Kang JS; Deluca PP; Lee KC
Expert Opin Emerg Drugs; 2009 Jun; 14(2):363-80. PubMed ID: 19453284
[TBL] [Abstract][Full Text] [Related]
18. In vitro refolding of PEGylated lipase.
Kim MY; Kwon JS; Kim HJ; Lee EK
J Biotechnol; 2007 Aug; 131(2):177-9. PubMed ID: 17683821
[TBL] [Abstract][Full Text] [Related]
19. Protein carboxyl amidation increases the potential extent of protein polyethylene glycol conjugation.
Li S; Yang Z; Sun X; Tan Y; Yagi S; Hoffman RM
Anal Biochem; 2004 Jul; 330(2):264-71. PubMed ID: 15203332
[TBL] [Abstract][Full Text] [Related]
20. Pegylation: engineering improved biopharmaceuticals for oncology.
Molineux G
Pharmacotherapy; 2003 Aug; 23(8 Pt 2):3S-8S. PubMed ID: 12921216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
